Web3

Home Web3 Page 5

Kelp DAO Exploit Sparks Aave Liquidity Crunch, $6.2 Billion Withdrawal Panic – Decrypt

0
Kelp DAO Exploit Sparks Aave Liquidity Crunch, .2 Billion Withdrawal Panic – Decrypt



In brief

Aave users struggled to withdraw funds from Aave after attackers borrowed with stolen rsETH on the platform, spiking a core market’s so-called utilization rate.
The funds were plundered from a LayerZero-powered bridge, in what onlookers described as DeFi’s biggest exploit so far this year.
Early Sunday, DefiLlama’s 0xngmi said Aave had faced $6.2 billion in net withdrawals, while Spark’s monetsupply.eth pointed to “negative secondary effects.”

Less than a day after attackers drained $291 million in crypto from infrastructure linked to decentralized finance project Kelp DAO, users on Aave, one of DeFi’s most battle-tested protocols, struggled to withdraw funds amid a liquidity crunch.

A bridge that typically allows users to move an asset called rsETH from one network to another was exploited on Saturday, prompting Aave to freeze markets tied to the token, which attackers had used to borrow funds from the platform, the lending protocol said in an X post.

Meanwhile, Kelp DAO said in an X post that it had “paused rsETH contracts” across Ethereum’s mainnet and several layer-2 scaling networks as it investigates suspicious activity.

The attackers’ activity on Aave caused the so-called utilization rate of a core lending pool to spike to 100%, signaling that users who previously deposited Ethereum and wrapped Ethereum have been left with little to no liquidity to withdraw, Aavescan data showed.

An hour before Aave locked down the markets, blockchain security firm PeckShield flagged a transaction showing 116,500 rsETH, worth $291 million at the time, flowing to a fresh wallet.

The attackers didn’t abscond with rsETH that had been maliciously released from the bridge. Rather, they used Aave to borrow regular funds, creating “massive bad debt,” Francesco Andreoli, head of developer relations at Consensys and MetaMask, said in an X post. (Disclaimer: Consensys is one of many investors in an editorially independent Decrypt.)

Aave’s governance token plunged to $90.13 on Sunday, a 16% decrease over the past day, according to CoinGecko. Ethereum fell 2% to $2,300 over the same period.

As users struggled to withdraw from Aave, they began borrowing against their deposits in stablecoins, straining the liquidity further as a sign of “negative secondary effects,” said monetsupply.eth, the pseudonymous head of strategy at DeFi project Spark, in an X post.

The Kelp DAO exploit and ensuing fallout on Aave prompted a massive wave of withdrawals from several DeFi protocols, even those that were unaffected, according to 0xngmi, the pseudonymous co-founder of data provider DefiLlama. On a net basis, users had yanked $6.2 billion from Aave alone by early Sunday, they said in an X post.

With contagion appearing to spread, DeFi’s latest exploit provides “a lot of ammo” for critics skeptical of systems that seek to replace traditional financial intermediaries with code, Salman Banei, general counsel at Plume, a network focused on tokenization, said in an X post.

Kelp DAO issues rsETH, a liquid staking token that allows users to earn Ethereum staking and EigenLayer restaking rewards. It acts as a tradeable “receipt” for Kelp DAO depositors. The Kelp DAO bridge was built on top of infrastructure designed by LayerZero, a protocol that allows DeFi applications to send messages and transfer assets across blockchains.

Stacy Muur, a noted blockchain researcher, said in an X post that the exploit appeared to rely on a single point of failure. She wrote that a “phantom” message used by attackers essentially tricked Kelp DAO’s bridge into releasing rsETH on Ethereum without removing a corresponding amount of tokens from circulation on Ethereum layer-2 Unichain.

Nonetheless, some onlookers were eager to find a path forward, including crypto entrepreneur and Tron founder Justin Sun. He attempted to negotiate, arguing that the attackers would ultimately struggle to spend the stolen funds.

“How much [do] you want?” he asked them in an X post. “It’s simply not worth it to sacrifice both Aave and Kelp DAO and let them go down over this hack.”

Daily Debrief Newsletter

Start every day with the top news stories right now, plus original features, a podcast, videos and more.



Source link

Cregis Shines at Paris Blockchain Week 2026, Accelerating European Expansion | Web3Wire

0
Cregis Shines at Paris Blockchain Week 2026, Accelerating European Expansion | Web3Wire


PARIS, April 19, 2026 (GLOBE NEWSWIRE) — From April 15–16, 2026, one of Europe’s premier blockchain events, Paris Blockchain Week 2026, concluded in Paris, France. Under the theme “The Bridge Between TradFi and Digital Assets,” the conference brought together regulators, financial institutions, Web3 projects, and infrastructure providers to explore the convergence of digital assets and traditional finance.

As a leading digital asset infrastructure provider, Cregis engaged with banks, payment providers, Web3 projects, and enterprise clients at Booth 20A. The company showcased its expertise in institutional custody, corporate wallets, and payment infrastructure, sharing its global experience and advancing its strategic presence in Europe.

From Narrative to Implementation: Europe Accelerates Institutional AdoptionOn the regulatory front, frameworks such as MiCA are providing clarity and predictability for the market. Many financial institutions and payment providers at the conference noted that clear regulations are a key catalyst for institutional adoption and lay the foundation for broader applications of digital assets.

Stablecoins and on-chain payments emerged as a central discussion point. Across cross-border payments, corporate settlements, and treasury management, stablecoins are evolving from crypto-native tools into essential infrastructure connecting traditional finance with the on-chain economy. “How to build efficient, compliant settlement networks” became a frequent topic of discussion.

Corporate demand is also shifting. Unlike the past, which focused primarily on trading infrastructure, today’s market prioritizes system-wide capabilities such as custody security, treasury efficiency, and compliance and risk management frameworks. This trend reflects the growing integration of digital assets into enterprise-grade financial systems.

Paris Blockchain Week: A Key Convergence of Regulation, Institutions, and TechnologyParis Blockchain Week has reaffirmed its role as a critical connector in Europe’s blockchain ecosystem. From regulators outlining compliance pathways to traditional financial institutions exploring digital asset adoption, and Web3 enterprises developing infrastructure and real-world use cases, the conference highlighted a clear trend: digital assets are increasingly integrating with existing financial systems rather than existing as isolated ecosystems.

Europe’s unique position stands out. Its relatively mature regulatory landscape provides stability for industry development, while stringent compliance requirements set higher standards for infrastructure. This makes Europe not only a regulatory stronghold but also a testing ground for real-world digital asset adoption.

Cregis: Entering Europe Market Through Infrastructure ExcellenceAt the event, Cregis engaged with potential partners on institutional custody, stablecoin payments, and on-chain treasury management, confirming strong demand for compliant digital asset infrastructure in Europe.

Richard, Co-Founder of Cregis, said, “It’s clear from this conference that Europe is entering a development stage focused on compliance and infrastructure. Institutional clients prioritize security, scalability, and compatibility with existing financial systems, perfectly aligned with the capabilities we’ve built.”

He added that Cregis will continue expanding in Europe, exploring partnerships with local banks, payment providers, and enterprises to advance stablecoin payments, on-chain settlements, and corporate wallet solutions in real business scenarios.

“We are seeing double-digit growth across our pan-European client base, which reinforces our confidence in the region’s long-term opportunity,” said Shawn Yan, CEO and Founder of Cregis. “Europe’s evolving policy environment, especially the greater regulatory clarity created by MiCA, is opening up meaningful space for compliant digital asset adoption at scale. Given this momentum, we are formally increasing our investment in Europe in 2026 to better serve customers across the region. Our focus is to support different client needs with the right mix of payment infrastructure, governance controls and deployment models — from always-on treasury and settlement workflows to private, institution-grade custody infrastructure.”

As the digital asset industry enters a new phase, infrastructure for payments, custody, and treasury management is becoming a key bridge between TradFi and Web3. Paris Blockchain Week 2026 allowed Cregis to deepen connections with global partners and sharpen its strategic direction in Europe. With regulatory clarity improving and institutional demand rising, Europe is poised to become a major growth engine for digital asset infrastructure.

About CregisCregis is a global provider of enterprise-grade digital asset infrastructure, offering secure, scalable, and compliant solutions for institutional clients.

Its core offerings—MPC-based self-custody wallets, Wallet-as-a-Service, and crypto payment solutions—are trusted by over 3,500 crypto exchanges, fintech companies, digital banks, payment service providers (PSPs), forex brokers, and Web3 businesses to seamlessly and securely accept, send, and manage digital assets.

Contact

Marketing DirectorJaniceCregisjanice@cregis.io

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5bebd304-3269-4385-9874-50701ff2353a

About Web3Wire Web3Wire – Information, news, press releases, events and research articles about Web3, Metaverse, Blockchain, Artificial Intelligence, Cryptocurrencies, Decentralized Finance, NFTs and Gaming. Visit Web3Wire for Web3 News and Events, Block3Wire for the latest Blockchain news and Meta3Wire to stay updated with Metaverse News.



Source link

Direct Meds GLP-1 2026: Claims Examined, Pricing Verified & What Consumers Should Confirm Before Buying | Web3Wire

0
Direct Meds GLP-1 2026: Claims Examined, Pricing Verified & What Consumers Should Confirm Before Buying | Web3Wire


New York City, NY, April 18, 2026 (GLOBE NEWSWIRE) — You’ve done the diets. Probably more than once. You’ve tracked calories, cut carbs, tried intermittent fasting, started gym memberships in January and quietly stopped going in March. And none of it has moved the needle the way you needed it to.

Here’s something worth understanding: for many people, that struggle isn’t about willpower. It’s about biology. The human body is built to resist weight loss, hunger hormones ramp up, metabolism slows down, and the brain sends relentless signals to eat more. For decades, conventional dieting tried to override this system through restriction alone. It’s a hard way to fight when the odds are against you.

GLP-1 medications, a class of prescription treatments that work directly on the hormonal signals that control hunger and fullness, represent one of the most significant shifts in medically supervised weight management in recent memory. In large clinical trials of FDA-approved GLP-1 active ingredients, participants lost a significant amount of weight when they also followed a diet and exercised. Results may vary based on starting weight and program adherence.

Direct Meds is a telehealth platform that connects patients with licensed physicians who can evaluate whether a compounded GLP-1 medication may be appropriate for their individual needs and, if prescribed, facilitate access to it with shipping included. No insurance hoops. No clinic waiting rooms. No pharmacy trips.

Is it the right path for you? That’s what this review breaks down.

What Is Direct Meds?

Direct Meds is a U.S.-based telehealth platform that provides patients with access to licensed physicians who evaluate their suitability for compounded GLP-1 weight management medications. It is not a pharmacy and not a drug manufacturer; it is the access layer between patients seeking medically supervised weight support and the licensed medical professionals who make all prescribing decisions.

The platform has served over 180,000 customers and holds LegitScript certification, a recognized standard for legitimate online healthcare platforms that verifies compliance with applicable laws and regulations. 

What Direct Meds offers through its program: Following a completed online medical intake, patients are connected with board-certified physicians who review their health history and determine whether a compounded GLP-1 medication is clinically appropriate. If prescribed, medications are prepared by U.S.-based compounding pharmacies and shipped directly to the patient’s door.

Two formats available: Direct Meds currently offers compounded GLP-1 medications in both injectable and sublingual (oral drop) formats, giving patients and their physicians flexibility based on individual preference and clinical suitability.

Important distinction: Compounded medications are not FDA-approved. They are prepared by licensed compounding pharmacies to meet individual patient needs when commercially available options are not suitable for their personalized needs. The active ingredients used, semaglutide and tirzepatide, are the same active ingredients found in several FDA-approved products, but the compounded formulations themselves have not been reviewed by the FDA for safety, effectiveness, or manufacturing quality.

Direct Meds operates as the coordination platform: it handles the intake process, the telehealth consultation, and the logistics. The prescribing and dispensing are handled by independent licensed physicians and separate licensed pharmacies.

Does Direct Meds Really Work?

To answer this clearly, it’s important to separate two distinct questions: does the Direct Meds platform work as a service, and does GLP-1 medication work as a treatment for weight management?

On GLP-1 medication efficacy: The active ingredients that Direct Meds’ compounded medications are based on, semaglutide and tirzepatide, have been studied extensively in large clinical trials of their FDA-approved versions. In those trials, semaglutide demonstrated average weight reductions of around 15% of body weight over 68 weeks when used alongside a reduced-calorie diet and increased physical activity. Tirzepatide showed even larger average reductions in comparable studies. These are significant outcomes from serious peer-reviewed clinical research.

Note – ” The active ingredients used, semaglutide and tirzepatide, are the same active ingredients found in several FDA-approved products, but the compounded formulations themselves have not been reviewed by the FDA for safety, effectiveness, or manufacturing quality.”

On the Direct Meds platform specifically: The service has built a strong track record as an access pathway with over 180,000 customers served, a 4.8/5 rating on Trustpilot, and LegitScript certification confirming operational standards. What the platform delivers is physician-supervised access: a licensed doctor reviews your health profile, makes an independent prescribing decision, and if appropriate, facilitates access to compounded medications prepared by licensed U.S. pharmacies.

Put simply: if GLP-1 medication is appropriate for your individual situation, a decision only a licensed physician can make, Direct Meds provides a streamlined, medically supervised pathway to access it. Results may vary based on starting weight, program adherence, and individual health factors.

>> For more information or to learn about available treatment options, visit DirectMeds

Is DirectMeds Legitimate?

This question comes up with any telehealth platform offering compounded GLP-1 medications and it’s worth answering directly, because the space has attracted some illegitimate operators alongside genuine services.

Direct Meds is a legitimate platform. It holds active LegitScript certification, which requires meeting ongoing standards for licensed pharmacy partnerships, prescription practices, and regulatory compliance. It has served over 180,000 customers. It maintains a 4.8/5 rating on Trustpilot across thousands of verified reviews. Medications are dispensed by 503A-designated compounding pharmacies.

The warning worth heeding about the broader market: Not all providers in this space meet the same standards. The FDA has documented counterfeit compounded GLP-1 products in the U.S. containing unknown or incorrect ingredients. When seeking any compounded medication, using a LegitScript-certified platform that partners with licensed 503A pharmacies is a meaningful quality indicator. Always ensure your medication is being prescribed by a licensed physician based on a proper medical evaluation.

Direct Meds is a legitimate platform by the measurable standards available. But as with any compounded medication program, it is essential to understand that compounded formulations are not FDA-approved, the regulatory environment is evolving, and only a licensed physician can determine whether this type of treatment is appropriate for your individual health situation.

>> For more information or to learn about available treatment options, visit DirectMeds

How Does Direct Meds Work? The Science Behind It

Understanding Direct Meds means understanding two things: how GLP-1 medications work physiologically and how the Direct Meds platform is structured to provide physician-supervised access to them.

The science behind GLP-1 medications:

GLP-1 stands for glucagon-like peptide-1, a hormone your gut naturally releases in response to eating. It plays several key roles in appetite and blood sugar regulation, and GLP-1 receptor agonist medications are designed to mimic and amplify these effects.

Appetite suppression via the brain: GLP-1 receptors are present in the hypothalamus, the brain region responsible for hunger and satiety signals. GLP-1 receptor activation tells your brain you are full, reducing the drive to eat. Many people on GLP-1 medications describe this as food cravings simply switching off, not a matter of willpower, but a genuine physiological shift in appetite signaling.

Slowed gastric emptying: GLP-1 medications slow the rate at which food leaves the stomach. This means you feel full sooner and stay full longer after eating smaller amounts. The practical effect is a natural reduction in caloric intake without the misery of constant hunger.

Blood sugar regulation: GLP-1 medications stimulate insulin release in response to food intake and suppress glucagon, the hormone that raises blood sugar. This mechanism is particularly relevant for people with blood sugar management challenges.

Tirzepatide’s dual mechanism: Direct Meds offers compounded formulations based on two active ingredients. Semaglutide activates GLP-1 receptors. Tirzepatide activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors, a dual-action approach that has been associated with larger average weight reductions in clinical trials of the FDA-approved versions. In a 2025 head-to-head clinical trial published in the New England Journal of Medicine, tirzepatide produced greater average body weight reduction over 72 weeks compared to semaglutide. These results are from studies of FDA-approved versions; compounded formulations are not FDA-approved and have not been independently reviewed for efficacy.

How the Direct Meds platform works:

Step 1 — Online medical intake: You complete a comprehensive health questionnaire covering your medical history, current medications, health goals, and relevant risk factors. This is the information the physician uses to evaluate your suitability.

Step 2 — Physician evaluation: A licensed physician independently reviews your intake information. Telehealth consultations are included. The physician makes all prescribing decisions based on your individual clinical profile, no prescription is issued automatically.

Step 3 — Pharmacy fulfillment and delivery: If prescribed, your compounded GLP-1 medication is prepared by a U.S.-based 503A compounding pharmacy and shipped directly to your door, typically within 1-2 days. Nursing team support is available throughout your treatment.

>> For more information or to learn about available treatment options, visit DirectMeds

Powerful Features of Direct Meds: What Makes It Unique?

The compounded GLP-1 telehealth space has grown considerably. Here is what specifically distinguishes the Direct Meds platform.

1. LegitScript Certified: LegitScript certification is not automatic; it requires meeting ongoing operational standards around pharmacy partnerships, prescription requirements, and regulatory compliance. Direct Meds maintains active LegitScript certification, which provides a level of third-party verification that not all providers in this space can claim.

2. Both Injectable and Oral (Sublingual) Formats:  Many GLP-1 telehealth providers offer only injectable formats. Direct Meds provides both compounded injectable vials and sublingual oral drops thereby giving physicians flexibility to prescribe the format best suited to individual patient needs and preferences.

3. Dedicated Nursing Team Support:  Direct Meds is one of the only providers with a dedicated nursing team that supports patients throughout their treatment. This means ongoing access to qualified clinical support for questions about dosing, side effects, titration, and progress not just a prescription and a product.

4. Telehealth Consultation Included:  The physician consultation is built into the program. Board-certified physicians review health profiles and make independent prescribing decisions. Telehealth visits are included, not billed separately as an add-on.

5. 1-2 Day Shipping, No Hidden Fees:  If prescribed, medications ship from licensed U.S. compounding pharmacies with shipping included. The platform is transparent about pricing; same price every dose, no membership fees, cancel anytime. This is a meaningful differentiator in a space where hidden costs and recurring billing surprises are common complaints.

6. 180,000+ Patients Served:  Scale matters in healthcare because it reflects operational experience managing real patient outcomes at volume. Direct Meds’ track record of over 180,000 customers served provides a meaningful signal about platform reliability and operational maturity.

7. Optional B-12 Supplementation:  Vitamin B-12 supplementation is included as an optional add-on at no additional charge. B-12 supports energy metabolism and neurological function, two areas commonly relevant to weight management program participants.

Direct Meds Medication Options — What’s Available?

Direct Meds offers compounded medications prepared by licensed 503A compounding pharmacies. Here is what the program currently makes available, subject to physician prescribing decisions.

Important: Compounded medications are not FDA-approved. They are prepared by licensed compounding pharmacies to meet individual patient needs when commercially available options are not suitable for their personalized needs. Efficacy data referenced below are drawn from studies of FDA-approved versions of these active ingredients, not from the compounded formulations.

MedicationFormat OptionsMechanismCompounded SemaglutideInjectable vial or sublingual dropsGLP-1 receptor agonist — supports appetite regulation and gastric emptyingCompounded TirzepatideInjectable vial or sublingual dropsGLP-1 and GIP dual receptor agonist — supports appetite regulation via two hormonal pathwaysOptional: Vitamin B-12Included as add-onSupports energy metabolism — included at no additional charge

Compounded Semaglutide — Semaglutide is the active ingredient in several FDA-approved GLP-1 products for diabetes and weight management. As a GLP-1 receptor agonist, it works by activating GLP-1 receptors in the brain and gut, suppressing appetite, slowing gastric emptying, and supporting blood sugar regulation. Direct Meds offers compounded semaglutide in both injectable and sublingual oral drop formats. The compounded version is prepared by a licensed U.S. 503A pharmacy and is not FDA-approved as a finished product.

Compounded Tirzepatide — Tirzepatide is the active ingredient in several FDA-approved products for diabetes and weight management. Unlike semaglutide, which acts solely on GLP-1 receptors, tirzepatide also activates GIP receptors, a dual mechanism that clinical trials of FDA-approved tirzepatide have associated with greater average weight reductions. These results are from studies of FDA-approved versions; compounded tirzepatide is not FDA-approved and has not been independently reviewed for these outcomes. Results may vary.

Injectable vs. Sublingual: The injectable format uses a standard subcutaneous injection, typically once weekly. The sublingual oral drops dissolve under the tongue. Your physician determines which format is most appropriate based on your individual clinical situation. The sublingual format is particularly relevant for patients who prefer to avoid injections entirely.

>> For more information or to learn about available treatment options, visit DirectMeds

How to Access Direct Meds in 3 Simple Steps

The entire process, from initial intake to receiving medication, is designed to be completed entirely online, without clinic visits, insurance submissions, or pharmacy trips.

Step 1: Complete the Online Medical IntakeVisit the official Direct Meds website and complete the confidential online health questionnaire. It covers your medical history, current medications, weight history, health goals, and relevant risk factors. This typically takes a few minutes and is the foundation of your physician’s evaluation.

Step 2: Physician Reviews and Prescribes (if appropriate)A board-certified physician independently reviews your intake information. Telehealth consultations are included to allow you to discuss your situation, ask questions about treatment options, and understand the risks and potential benefits. If the physician determines that a compounded GLP-1 medication is appropriate for your individual needs, a prescription is issued. Not every patient will qualify. 

Step 3: Medication Ships Directly to YouIf prescribed, your compounded medication is prepared by a licensed U.S. compounding pharmacy and shipped directly to your door with shipping included. Direct Meds states delivery typically within 1-2 days of order processing. Ongoing nursing team support is available throughout your treatment to address any questions about dosing, side effects, or progress.

Who Can Access Direct Meds?

Direct Meds is a physician-gated program meaning the physician’s independent medical evaluation determines who is appropriate for treatment. That said, the following profiles are most commonly associated with suitable candidacy for compounded GLP-1 treatment based on general clinical guidance.

Adults managing overweight or obesity where lifestyle interventions alone have not been sufficient. GLP-1 medications are specifically indicated in the clinical context of obesity or overweight with weight-related health conditions. If you have a BMI of 30 or above, or 27 or above with a related health condition, you may be a candidate for evaluation.

Adults who have found hunger and cravings to be the primary obstacle to sustained weight loss. GLP-1 medications work on the neurological signals that drive hunger. For people who have found that diet plans fail not from lack of effort but from the relentless biological pull to eat more, this mechanism addresses the root issue not just the symptom.

Adults seeking a convenient, private, fully remote program. The entire Direct Meds process happens from home. No clinic visits, no waiting rooms, no conversations at a pharmacy counter. For many people, that removal of friction and social discomfort is what makes medically supported weight management actually accessible.

Adults without insurance coverage for GLP-1 medications. Brand-name GLP-1 medications can cost well over $1,000 per month without insurance. A significant proportion of people who could benefit from them are effectively priced out. Compounded medications may be offered at different price points because they are prepared in limited quantities for specific patient needs.

Who should not proceed without detailed medical review: GLP-1 medications carry specific contraindications. People with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) should not use GLP-1 receptor agonists. People with a history of pancreatitis, certain gastrointestinal conditions, or who are pregnant or breastfeeding require careful physician evaluation. The medical intake process is designed to screen for these, but full transparency about your health history is essential.

>> For more information or to learn about available treatment options, visit DirectMeds

Direct Meds Health & Safety Report

This section requires both honesty about known risks and precision about what the evidence base actually covers.

On the active ingredients: Semaglutide and tirzepatide have been extensively studied in large clinical trials of their FDA-approved versions. The side effect and safety profiles from those trials are the most reliable reference point available.

Commonly reported side effects of GLP-1 active ingredients (from clinical trials of FDA-approved versions):

Nausea — the most commonly reported side effect, especially during initial titration; typically diminishes as the body adjustsVomiting — less common but possible, particularly at higher doses or during dose increasesDiarrhea or constipation — GI effects are the most frequently reported category overallAbdominal pain or discomfortFatigue — reported by some patients during the adjustment periodInjection site reactions — redness, mild discomfort at the injection site

Rare but serious risks (from clinical trial data of FDA-approved versions):

Possible thyroid tumors including thyroid cancer — GLP-1 medications should not be used by people with a personal or family history of medullary thyroid carcinoma or MEN 2Acute pancreatitis — cases have been reported; discontinue and seek medical attention if you experience persistent severe abdominal painGallbladder disease — including gallstonesHypoglycemia — particularly when combined with other glucose-lowering medicationsIncreased heart rate

The compounded medication caveat: Compounded formulations of semaglutide and tirzepatide have not undergone FDA review for safety, effectiveness, or manufacturing quality. Using a platform that partners with licensed 503A pharmacies, as Direct Meds does, provides meaningful quality controls, but does not equate to FDA approval.

Direct Meds GLP-1 Side Effects: What You Should Know Before Starting

Side effects are a real part of any prescription treatment, and GLP-1 medications are no exception. Understanding what to expect and how to manage it is an important part of making an informed decision. 

Note: The side effect data below is drawn from clinical trials of FDA-approved versions of semaglutide and tirzepatide, as compounded formulations have not been independently reviewed by the FDA for safety or effectiveness. Your prescribing physician will review side effects specific to your health profile during consultation.

Gastrointestinal effects — the most common category: Nausea is the most frequently reported side effect across GLP-1 clinical trials, particularly during the initial weeks of treatment and when doses are increased. Most patients find that nausea is manageable and reduces significantly as the body adjusts. Vomiting, diarrhea, constipation, and abdominal discomfort also occur in a meaningful proportion of users, with frequency varying between semaglutide and tirzepatide based on clinical trial data.

Fatigue — reported by some patients: Some people experience fatigue during the initial adjustment phase, particularly in the first few weeks. This tends to improve as the body acclimates to the medication. Staying well hydrated and maintaining adequate nutrition supports energy levels during this period.

Injection site reactions: For patients on the injectable format, mild redness, swelling, or discomfort at the injection site can occur. Rotating injection sites and following proper injection technique (which is covered in the instructions provided) minimizes this risk.

Rare but serious risks — know these before starting:

Possible thyroid tumors: In animal studies, GLP-1 receptor agonists caused thyroid tumors including thyroid cancer. It is unknown if this applies to humans, but GLP-1 medications should not be used by anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)Pancreatitis: Cases of acute pancreatitis have been reported. Discontinue treatment and seek medical attention immediately if you experience persistent severe abdominal painGallbladder disease: Gallstones and gallbladder inflammation have been reported, especially with rapid weight lossLow blood sugar (hypoglycemia): More relevant when combined with insulin or other glucose-lowering medicationsIncreased resting heart rate: Some patients experience a modest increaseKidney issues: GI side effects can lead to dehydration, which can affect kidney function — staying hydrated is important

Managing side effects effectively: The most important thing you can do is stay in communication with your Direct Meds medical team. The nursing support available through the program exists precisely for this, to help you navigate the adjustment period, manage symptoms, and titrate your dose appropriately. Don’t stop treatment without consulting your physician.

For most patients who are appropriate candidates, side effects are manageable and temporary. The adjustment period is real, but so are the reasons to work through it with proper medical support.

What Are the Key Benefits of the Direct Meds GLP-1 Program?  

Here is what the Direct Meds program can realistically offer, grounded in both the clinical evidence for the active ingredients and the practical advantages of the platform structure. All outcome claims reflect results from studies of FDA-approved versions of these active ingredients; results may vary based on starting weight and program adherence.

1. Meaningful Appetite Suppression: The most consistently reported experience among GLP-1 users and the one that makes the biggest difference to daily life is the reduction or elimination of food cravings and constant hunger. Many patients describe it as the ‘food noise’ simply switching off. For people whose primary obstacle to weight management has been the relentless biological drive to eat more, this change is profound. Results may vary.

2. Support for Sustained Weight Management:  In large clinical trials of FDA-approved semaglutide and tirzepatide, participants experienced significant average reductions in body weight when used alongside reduced-calorie diets and increased physical activity. These results accumulated over months, not weeks. The sustained nature of the effect distinguishes GLP-1 treatment from approaches that produce short-term loss followed by rapid regain. Results from studies of FDA-approved versions; compounded medications are not FDA-approved. Results may vary.

3. Improved Relationship with Food:  Beyond raw numbers, many patients report a qualitative shift in their relationship with food — eating smaller portions naturally, choosing different foods without effortful restriction, stopping eating when full rather than continuing past comfort. These behavioral changes happen as a downstream effect of the hormonal signaling shift, not through willpower.

4. Cardiometabolic Benefits: Clinical trials of FDA-approved GLP-1 active ingredients have documented improvements in blood pressure, blood sugar regulation, and cardiovascular risk markers in study participants. These metabolic benefits are a significant part of why GLP-1 medications have attracted such substantial medical and scientific attention beyond their weight loss effects. 

Note – ” The active ingredients used, semaglutide and tirzepatide, are the same active ingredients found in several FDA-approved products, but the compounded formulations themselves have not been reviewed by the FDA for safety, effectiveness, or manufacturing quality.”

5. Fully Remote, Private, and Convenient:  From intake to delivery, nothing about the Direct Meds program requires leaving home. There are no waiting rooms, no clinic visits, no insurance submissions, and no pharmacy counter conversations. For many patients this removes the barrier that previously stopped them from accessing medical support entirely.

6. Both Injectable and Oral Formats Available:  Not everyone wants to self-inject. The sublingual drop format provides an effective alternative delivery option. Your physician determines which format is most clinically appropriate for you.

7. Ongoing Nursing Team Support:  Direct Meds operates one of the few platforms in this space with a dedicated nursing team available for ongoing patient support. When you have questions about side effects, dosing, or what you’re experiencing, a qualified clinical professional is accessible. 

8. Transparent, All-Inclusive Pricing:  The program costs the same every dose, with no hidden membership fees, no surprise billing, and the ability to cancel anytime. For a category notorious for escalating subscription traps and opaque billing, this straightforwardness is a real advantage.

>> For more information or to learn about available treatment options, visit DirectMeds

Direct Meds Reviews: Customer Complaints and Consumer Reports

A complete and honest review includes the criticisms. Direct Meds has a strong average rating across thousands of Trustpilot reviews, but real concerns do appear in the feedback and they’re worth understanding before committing.

Side effects during the adjustment period — The most common complaint category about at Direct Meds GLP-1 program is nausea, particularly in the first weeks of treatment or when doses are increased. The platform’s nursing team support is specifically designed to help navigate this, but it’s a real experience that some reviews describe as difficult in the short term.

Pricing relative to some competitors — While Direct Meds’ pricing is structured to be more accessible than brand-name alternatives, some patient reviews note that costs add up over the months of sustained treatment typically required to maintain results. This is not a Direct Meds-specific criticism, GLP-1 treatment generally represents a meaningful ongoing investment, but it’s an honest cost consideration to factor in.

Onboarding timeline — A small number of reviews mention the onboarding process taking slightly longer than expected. Physician review, prescription processing, and pharmacy preparation are real steps that take time. The stated 1-2 day delivery applies after the prescription is processed and the order ships.

Availability may vary by state — Telehealth prescription practices and compounding pharmacy regulations vary by state. Some patients in certain states may face additional requirements or limited availability. Confirm with Direct Meds directly about your state before beginning the intake process.

>> For more information or to learn about available treatment options, visit DirectMeds

Real Direct Meds User Reviews & Testimonials: What Customers Are Saying

Here are verified patient testimonials drawn from the Direct Meds platform. Customer results are not independently verified. Individual results may vary based on starting weight and program adherence. These represent individual experiences and are not typical results.

Why Is the Direct Meds GLP-1 Program Trending in the United States?

The growth of compounded GLP-1 programs reflects several converging factors and understanding them gives important context for evaluating whether this is a genuine medical trend or just marketing momentum.

The GLP-1 access gap is enormous. Brand-name GLP-1 medications like semaglutide and tirzepatide products have been among the most discussed medications of the last several years not because of pharmaceutical marketing, but because of the genuinely significant clinical outcomes documented in large trials. The problem is that brand-name versions cost well over $1,000 per month without insurance, and insurance coverage remains inconsistent and difficult to obtain. An estimated 100+ million Americans meet clinical criteria for obesity treatment, yet the majority cannot access the brand-name medications at those price points.

Telehealth removed the clinical access barrier. Before telehealth GLP-1 programs existed, accessing medically supervised weight management treatment meant navigating a system stacked against patients — referrals, specialist waitlists, insurance prior authorizations, in-person visits, and a medical culture that frequently dismissed weight concerns. Telehealth platforms like Direct Meds collapsed that process into a fully online workflow accessible from anywhere.

Compounded medications offered a price point that worked. Compounded medications may be offered at different price points because they are prepared in limited quantities for specific patient needs. This makes physician-supervised GLP-1 access financially viable for patients who would otherwise be entirely priced out. It is important to note that compounded medications are not FDA-approved and are not the same as the branded products but for appropriately evaluated patients, they have provided access to a genuinely effective class of treatment.

The social proof feedback loop. Few medical treatments generate word-of-mouth the way GLP-1 medications have. When patients experience meaningful changes in appetite, eating behavior, and body weight and share those experiences publicly, interest compounds quickly. The growth of patient communities discussing GLP-1 experiences has dramatically raised awareness of this treatment category across demographics that had previously never engaged with medically supervised weight management.

>> For more information or to learn about available treatment options, visit DirectMeds

Top Tips for Best Results with Direct Meds

GLP-1 medication does the heavy lifting on appetite regulation but the patients who see the most meaningful and sustained outcomes are those who pair the medication with consistent supporting habits. Here’s what makes the difference.

1. Be completely transparent in your medical intake: Your physician can only make a safe and appropriate prescribing decision based on accurate information. Your full medical history, current medications, and any health conditions must be disclosed completely. This protects you and it ensures your treatment plan is actually right for your situation.

2. Follow your titration schedule: GLP-1 medications are started at a low dose and increased gradually. This titration process is specifically designed to reduce GI side effects during the adjustment period. Don’t push to a higher dose faster than prescribed; the schedule exists for good clinical reasons.

3. Stay adequately hydrated: Reduced food intake and potential GI side effects both increase dehydration risk. Drinking sufficient water throughout the day is particularly important on GLP-1 treatment as it supports kidney function, reduces constipation risk, and helps manage the nausea that some patients experience.

4. Eat when you need to, even in small amounts: Many patients find their appetite dramatically reduced. While this is the intended effect, it is still important to maintain some nutritional intake to support muscle preservation during weight loss. Small, nutrient-dense meals are more important than eating to an arbitrary calorie target.

5. Communicate side effects promptly: Direct Meds’ nursing team is there for this exact purpose. If you’re experiencing nausea, GI discomfort, or anything unexpected, reach out. Dose adjustments, dietary guidance, and clinical support are available. Don’t silently suffer through side effects or quietly stop treatment without medical guidance.

6. Give the program time: The appetite and behavioral changes typically become most consistent after several weeks of stable dosing. Patients who judge the program at week two are often assessing before the medication has reached its full effect. Consistent patience through the titration period is one of the biggest predictors of positive outcomes.

How to Get Maximum Benefits from Direct Meds GLP-1 Treatment

GLP-1 medication addresses the biological side of the weight management equation. The lifestyle factors you pair with it determine how much of the potential benefit you actually realize and sustain.

Prioritize protein intake: Weight loss always involves some muscle loss alongside fat loss. Adequate protein intake supports muscle preservation, keeps you fuller for longer, and supports the energy and body composition outcomes most patients are aiming for. 

Incorporate resistance training: The combination of GLP-1 treatment and resistance exercise produces meaningfully better body composition outcomes than medication alone. Even 2-3 sessions per week of bodyweight exercises or light weights makes a difference. 

Support sleep: Sleep deprivation disrupts the same hormonal systems GLP-1 medications target particularly ghrelin (the hunger hormone) and leptin (the satiety hormone). Poor sleep can work directly against GLP-1’s appetite-suppressing effects. Treating sleep as a medical priority, not an afterthought, supports better overall outcomes.

Reduce ultra-processed food consumption gradually: Many patients report naturally gravitating toward less processed foods on GLP-1 treatment as cravings diminish. Supporting this shift intentionally accelerates the dietary quality improvements that the medication makes easier to achieve.

Limit alcohol: Alcohol is calorie-dense, disrupts sleep quality, lowers inhibitions around food choices, and can interact with GLP-1 treatment in ways that affect tolerability. Moderation is the sensible approach, with many patients finding that alcohol appeal also naturally diminishes on GLP-1 medication.

>> For more information or to learn about available treatment options, visit DirectMeds

Common Mistakes to Avoid with GLP-1 Treatment Through Direct Meds

The patients who struggle most on GLP-1 programs are typically those who approach it with one of several common misconceptions. Getting clear on these from the start makes a meaningful difference.

Skipping doses or stopping treatment abruptly: GLP-1 medications require consistent administration to maintain stable hormone levels. Skipping doses or stopping suddenlynot only reduces effectiveness but can result in rapid return of appetite and rapid weight regain. Any changes to your protocol should be discussed with your Direct Meds medical team first.

Expecting results without any lifestyle change: GLP-1 medications are prescribed alongside diet and exercise for a reason as the clinical trials that established their efficacy included lifestyle components. The medication dramatically lowers the effort required to change eating behavior, but does not mean zero effort. Patients who remain entirely sedentary and make no dietary adjustments will see more limited outcomes.

Judging outcomes too early: The adjustment period, typically the first 4-8 weeks, is when side effects are most pronounced and when the medication hasn’t yet reached its full effect at stable dosing. Assessing whether it’s ‘working’ at week two or three is premature. Many patients who experienced significant GI discomfort early describe dramatically improved experience and results at weeks 8-12.

Under-eating to the point of nutritional deficiency: Appetite suppression can be powerful enough that some patients barely eat at all in the early weeks. While reduced caloric intake is the goal, severely restricting nutrients creates risks including significant muscle loss, fatigue, and nutritional deficiencies. 

Combining with other weight loss medications or supplements without disclosure: Many OTC weight loss supplements, appetite suppressants, and even some herbal products can interact with GLP-1 medications or confound your physician’s assessment of how the treatment is working. 

Direct Meds GLP-1 Reviews: Pros

LegitScript certified180,000+ customers servedBoth injectable and sublingual oral drop formats availableDedicated nursing team for ongoing patient supportBoth compounded semaglutide and compounded tirzepatide availableTelehealth physician consultation included Transparent pricing Cancel anytime Shipping included if prescribed No insurance requiredOptional Vitamin B-12 supplementation at no additional charge4.8/5 Trustpilot rating across thousands of verified reviewsFully online Medications prepared by U.S.-based compounding pharmacies

Direct Meds GLP-1 Reviews: Cons

Compounded medications are not FDA-approvedGI side effects are common, particularly during the initial titration periodOngoing treatment cost Results require lifestyle commitment Weight regain is possible if treatment is discontinued Availability and eligibility may vary by state due to telehealth and compounding regulationsNot appropriate for people with history of MTC or MEN 2, pancreatitis, or certain other conditions

>> For more information or to learn about available treatment options, visit DirectMeds

Is Direct Meds Worth the Money? Value & Pricing Analysis

Cost is a central consideration in this category so let’s work through it properly.

Brand-name GLP-1 medications can cost over $1,000 per month without insurance. A significant proportion of people who could benefit from physician-supervised GLP-1 treatment are simply priced out of that option. That’s the market reality that compounded GLP-1 telehealth platforms operate within.

What Direct Meds offers: Compounded medications may be offered at different price points because they are prepared in limited quantities for specific patient needs not because they are cheaper alternatives to brand-name drugs in the way one consumer product might be cheaper than another. The regulatory context is different, and that distinction matters. Compounded medications are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness, or manufacturing quality.

What you’re paying for with Direct Meds: The program includes physician consultation (no separate billing), nursing team support throughout treatment, medication prepared by a licensed U.S. 503A compounding pharmacy, and shipping included. No insurance submissions. No hidden fees. No monthly membership tacked on. No clinic visit costs. For people who have genuinely struggled to access medically supervised weight management support due to cost or access barriers, this value proposition is meaningful.

Direct Meds is worth exploring if you are a candidate for physician-supervised GLP-1 treatment, your physician determines it is appropriate for your individual situation, and you understand the regulatory context of compounded medications fully. For people in that position, the platform offers a streamlined and cost-accessible pathway to a medically supported program that would otherwise be out of reach. Results may vary based on starting weight and program adherence.

The value calculation is ultimately your physician’s determination intersecting with your personal situation. What Direct Meds does is remove the access and cost barriers so that evaluation can actually happen.

Price of Direct Meds — Pricing Verified & Current Availability

Let’s talk through the actual numbers — because transparent pricing is one of Direct Meds’ stated commitments, and it’s worth laying out clearly.

Current Published Pricing:

Program OptionStarting PriceWhat’s IncludedCompounded GLP-1 InjectionsFrom $147Physician consultation, compounded medication, nursing support, shipping includedCompounded GLP-1 Oral Drops (Sublingual)From $199Physician consultation, compounded oral drops, nursing support, shipping includedOptional: Vitamin B-12No additional chargeIncluded as optional add-on with prescribed plans

What’s included in the program price:

Online physician evaluation Telehealth consultation Compounded medication prepared by a licensed U.S. 503A pharmacy, if prescribedDedicated nursing team support throughout your programShipping includedNo monthly membership feeCancel anytime

Putting the pricing in context:

OptionTypical CostNotesBrand-name GLP-1 (without insurance)$1,000+ per monthFDA-approved; insurance coverage inconsistentTraditional obesity medicine specialist visit$200–$500 per visitConsultation only — medication cost additionalDirect Meds compounded GLP-1 programFrom $147Includes physician consult, medication, nursing support, shipping. Not FDA-approved.

For readers of this site, using the link in this article goes directly to the official Direct Meds platform where current pricing and program details are available. Always verify pricing directly before enrolling.

>> For more information or to learn about available treatment options, visit DirectMeds

Where to Buy Direct Meds?

Direct Meds compounded GLP-1 medications are available exclusively through the official Direct Meds platform at directmeds.com. This is the only legitimate channel.

Compounded GLP-1 medications are prescription-only products that can only be legally dispensed based on a valid prescription from a licensed physician. They cannot be purchased from retailers, marketplaces, or third parties and any source claiming to sell them without a proper medical evaluation process should be treated with significant caution.

The process through the official platform: Complete the online health questionnaire, consult with a board-certified physician who makes an independent prescribing decision, and if prescribed, receive your medication from a licensed 503A U.S. compounding pharmacy, shipped directly to your door. Use the link in this article to go directly to the official Direct Meds program page.

>> For more information or to learn about available treatment options, visit DirectMeds

Can You Buy Direct Meds on Amazon, Walmart, or GNC?

No and it is important to understand why.

Compounded GLP-1 medications are prescription-only pharmaceutical compounds that cannot legally be sold on Amazon, Walmart, GNC, or any general retailer. Selling prescription medications without proper pharmacy licensure and a valid patient prescription is illegal in the United States.

What you will find on these platforms instead: OTC products marketed as “GLP-1 boosters” or “natural GLP-1 support” supplements. These are not GLP-1 receptor agonist medications. They do not contain semaglutide, tirzepatide, or any pharmaceutical GLP-1 compound. The FDA has issued clear guidance that over-the-counter GLP-1 supplements lack regulated clinical data and do not boost GLP-1 activity at clinically meaningful levels. These are supplement products with marketing language that borrows the GLP-1 name. They are not the same category as prescription GLP-1 medications.

The only legitimate path to compounded GLP-1 medications through Direct Meds is via the official platform, following a proper medical evaluation and valid prescription.

Direct Meds Official Website vs Third-Party Sellers: Where’s Best?

FactorOfficial Direct Meds PlatformThird-Party / Unverified SellersProduct authenticityCompounded by licensed U.S. 503A pharmacies per valid prescriptionCannot be verified Medical oversightBoard-certified physician evaluation includedNone Legal statusPrescription issued by licensed physician; dispensed by licensed 503A pharmacyIllegal Nursing supportDedicated nursing team included throughout programNonePlatform certificationLegitScript certifiedUnverified Transparent pricingPublished pricing, no hidden fees, cancel anytimeUnknown VerdictThe only legitimate optionDo not use 

There is no legitimate third-party market for Direct Meds’ compounded GLP-1 medications. The official platform is not just the recommended option; it is the only safe and legal one.

>> For more information or to learn about available treatment options, visit DirectMeds

Does Direct Meds Offer a Money-Back Guarantee? Return Policy Explained

Direct Meds’ refund policy is worth understanding clearly before you enroll, as it differs from typical consumer product return policies.

Prescription medications, including compounded GLP-1 formulations, cannot be returned once dispensed. This is standard across the pharmaceutical industry for safety and regulatory reasons. Once a compounded medication has been prepared for an individual patient and dispensed, it cannot be returned or redistributed.

What Direct Meds’ refund policy covers: Direct Meds offers a refund for the consultation fee if a patient is not approved for treatment following the physician evaluation meaning you are not charged for medication you were never prescribed. If you complete the intake, consult with a physician, and are determined not to be an appropriate candidate, you are not left paying for a product you cannot receive.

If you have concerns about a dispensed order: Direct Meds’ customer service team and nursing staff are available to address any issues with your order, shipping, or treatment. Given the platform’s track record and 4.8/5 Trustpilot rating across thousands of reviews, responsive customer support is a consistent feature of the service. For any order-specific concerns, contact Direct Meds directly through the official platform.

Frequently Asked Questions About Direct Meds

Q: Are Direct Meds’ compounded GLP-1 medications FDA-approved?A: No. Compounded medications are not FDA-approved. They are prepared by licensed compounding pharmacies to meet individual patient needs when commercially available options are not suitable for their personalized needs. The active ingredients, semaglutide and tirzepatide, are FDA-approved in their brand-name forms, but the compounded formulations have not been reviewed by the FDA for safety, effectiveness, or manufacturing quality. This is an important distinction to understand before enrolling.

Q: How soon can I receive my medication if prescribed?A: Direct Meds states that if prescribed, medications ship from licensed U.S. compounding pharmacies with shipping included, with delivery typically within 1-2 days of processing. 

Q: What is the difference between the injectable and oral drop formats?A: The injectable format involves a standard subcutaneous injection, typically administered once weekly. The sublingual oral drops dissolve under the tongue and represent a needle-free alternative delivery method. Y

Q: Do I need insurance?A: No. Direct Meds operates on a transparent cash-pay model. No insurance is required, no prior authorizations, and no insurance forms to submit. 

Q: What ongoing support is included?A: Direct Meds includes access to a dedicated nursing team throughout your program. This means you have qualified clinical support available for questions about dosing, titration, side effects, and progress without needing to book separate appointments or pay additional consultation fees.

>> For more information or to learn about available treatment options, visit DirectMeds

How Long Does It Take to See Results with Direct Meds?

Timeline expectations for GLP-1 treatment are important to set accurately because unrealistic expectations lead to frustration, and the actual evidence-based picture is genuinely compelling when understood correctly.

Weeks 1–4: The adjustment phase. GLP-1 medications are typically started at a low dose and titrated upward gradually to minimize gastrointestinal side effects. During this phase many patients report the beginning of appetite changes, food becomes less dominant, portions feel like less of a struggle. Some patients notice scale movement in the first month; others need more time to reach their therapeutic dose. Both are normal.

Weeks 4–12: Appetite regulation becomes consistent. As dose titration progresses and the body adjusts to GLP-1 receptor activation, the appetite-suppressing and satiety-supporting effects become more stable. Most patients report this as the phase where eating habits shift meaningfully, not through restriction but through a genuine reduction in hunger and craving intensity. Many patient testimonials on the Direct Meds platform describe this shift as the most striking and unexpected change.

Months 3–6: Progressive weight reduction. Clinical trial data from FDA-approved GLP-1 studies shows that the most substantial proportion of weight reduction typically occurs in this window, as patients reach their optimized therapeutic dose and the cumulative effect of reduced caloric intake compounds over time. 

Note – ” The active ingredients used, semaglutide and tirzepatide, are the same active ingredients found in several FDA-approved products, but the compounded formulations themselves have not been reviewed by the FDA for safety, effectiveness, or manufacturing quality.”

Beyond 6 months: Long-term maintenance. For many patients, GLP-1 treatment is a long-term program rather than a short course. Discussing long-term strategy with your physician from the outset ensures you are making a fully informed commitment.

Can I Use Direct Meds with Other Supplements or Medications?

This is a safety-critical question and one where complete transparency with your prescribing physician is non-negotiable.

Medications that require mandatory disclosure: Several medication classes interact meaningfully with GLP-1 receptor agonists. Insulin and other glucose-lowering medications can compound hypoglycemia risk when combined with GLP-1 treatment. Blood pressure medications may be affected as weight changes over time. Your physician reviews all current medications during the intake — do not omit anything.

OTC supplements: Even supplements that seem benign can affect GLP-1 treatment. Supplements containing berberine, fiber-based hunger suppressants, or stimulant-based ingredients may interact with the mechanism or the physiological effects of GLP-1 medications. 

Alcohol: GLP-1 medications slow gastric emptying, which can affect alcohol absorption; alcohol may be absorbed more slowly but then hit more intensely. 

The rule throughout: full disclosure in your medical intake, and prompt communication through the nursing team if anything changes. That is what the ongoing support structure is there for.

>> For more information or to learn about available treatment options, visit DirectMeds

Final Verdict on Direct Meds GLP-1: Is It Worth It?

We’ve covered the platform, the science, the regulatory context, the pricing, the side effects, the process, and the real patient feedback. Here’s the honest conclusion.

Direct Meds is one of the most accessible and well-structured telehealth platforms for physician-supervised compounded GLP-1 access currently available in the U.S.

That statement comes with important context, and any review that omits it isn’t being straight with you.

What Direct Meds does well: It removes the real access barriers, cost, friction, insurance complexity, and the clinical gatekeeping that has historically kept many people from pursuing medically supervised weight management. LegitScript certification, 503A licensed pharmacies, dedicated nursing team support, and a board-certified physician evaluation process together make this one of the more credibly structured platforms in a space that has attracted some less rigorous operators. Over 180,000 customers served and a 4.8/5 Trustpilot rating reflect genuine operational track record.

What you must understand going in: Compounded medications are not FDA-approved. They are prepared by licensed compounding pharmacies to meet individual patient needs when commercially available options are not suitable for their personalized needs. Compounded formulations have not been reviewed by the FDA for safety, effectiveness, or manufacturing quality. All clinical weight loss outcome data referenced in this review comes from studies of FDA-approved versions of these active ingredients not from compounded formulations. Results may vary based on starting weight and program adherence. The regulatory environment around compounded GLP-1 medications continues to evolve, and your physician will evaluate your individual situation in light of current guidelines.

Who Direct Meds is well-suited for:

Adults with obesity or overweight and related health conditions who have not achieved sufficient results through lifestyle interventions alonePeople who cannot access or afford brand-name GLP-1 medications through traditional insurance channelsPeople who want a fully remote, private, physician-supervised weight management pathway with ongoing nursing supportPeople prepared to approach this as a medically supervised program — with physician oversight, adherence to prescribed dosing, and realistic outcome expectations

Who should proceed with particular care:

Anyone with a personal or family history of medullary thyroid carcinoma or MEN 2 Anyone with a history of pancreatitis, certain gastrointestinal conditions, or complex medication interactions Anyone expecting rapid, guaranteed, or dramatic results without lifestyle engagement. GLP-1 treatment works alongside diet and exercise, not instead of it

For the right candidate, with clear eyes about both the opportunity and the regulatory context, Direct Meds offers a physician-supervised, cost-accessible pathway to a medically supported weight management program that would otherwise be out of reach for the majority of people who could benefit from it.

That is meaningful. And it’s what makes this platform worth serious consideration.

>> For more information or to learn about available treatment options, visit DirectMeds

Media details 

Email: help@direct-meds.com

Direct meds 

Address- 345 Grand Ave, Leonia, New Jersey

About Web3Wire Web3Wire – Information, news, press releases, events and research articles about Web3, Metaverse, Blockchain, Artificial Intelligence, Cryptocurrencies, Decentralized Finance, NFTs and Gaming. Visit Web3Wire for Web3 News and Events, Block3Wire for the latest Blockchain news and Meta3Wire to stay updated with Metaverse News.



Source link

GalaxyOne Head Wants Retail Investors to Stake More, Predict Less – Decrypt

0
GalaxyOne Head Wants Retail Investors to Stake More, Predict Less – Decrypt



In brief

GalaxyOne Head Zac Prince said he’s “not particularly excited” about prediction markets when it comes to enabling customers to build long-term wealth.
The executive highlighted the retail investment platform’s recent support of Solana staking and associated lending products in the firm’s pipeline.
Staking has enabled competitors like Coinbase to diversify revenue, while others like Robinhood have embraced prediction markets as growth drivers.

For Galaxy’s retail investment platform, enabling customers to bet on the news isn’t a priority, according to Zac Prince, head of GalaxyOne. Rather, the service that debuted in October is being built in a way that’s intended to reward investors’ patience, he told Decrypt.

Within the context of Galaxy’s broader business, Prince said the financial services and investment management firm is already in a good place as far as prediction markets are concerned, providing institutional clients with internal trading and risk management.

When it comes to consumers that GalaxyOne was built for, who have anywhere between $100,000 and $1 million in investible assets, he described prediction markets as tools that may not align with many affluent consumers for building long-term wealth.

“For individual consumers, I’m not particularly excited about it versus other things we have on our roadmap,” he said. “I haven’t been able to find a use case for someone who’s building a diversified portfolio—that they’re going to allocate to for the long term—for prediction markets.”



In some ways, the sentiment echoes commentary from Charles Schwab President and CEO Rick Wurster, who indicated this week that America’s largest discount brokerage would limit prediction-market access to wagers focused on financial events if it enters that territory.

Prince argued that there are two ways to be successful as a consumer-facing financial services offering: cater to investors who want time in the market to be the driving force, like Vanguard or Betterment, or seek customers that view themselves as active traders. 

Retail brokerages like Robinhood have embraced prediction markets by working with Kalshi, providing what analysts have described as a sports-fueled tailwind. Still, Prince indicated GalaxyOne isn’t trying to develop a platform “where you want people to log in every day.”

GalaxyOne began supporting Solana staking last month, enabling individuals to earn rewards by locking up tokens and participating in the process of validating the network’s transactions. In the not-too-distant future, Prince said that GalaxyOne plans to support Ethereum staking.

Until the end of this year, the firm has waived commissions on Solana staking rewards that customers receive. Lending services that GalaxyOne plans to offer in the future will allow investors to borrow against staked Solana and Ethereum while still earning rewards. 

“We’re really excited about that product,” Prince added.

Staking has enabled competitors like Coinbase to diversify revenue away from a reliance on trading fees, which tend to fluctuate alongside market conditions. The crypto exchange disclosed in February that it generated $677 million from staking in 2025, down 4% year-over-year, citing lower average crypto prices in a shareholder letter.

Currently, GalaxyOne’s customers are showing a preference for 8% returns on cash that the platform’s “premium yield” product supports, Prince said, describing the offering as among the most differentiated that the company has debuted so far.

This week, Galaxy announced that its retail investment platform was poised to begin accepting U.S. businesses and entities as customers. Prince noted that the move provides an all-in-one place for those customers to manage bank, brokerage, and crypto accounts.

“I think business accounts will get some traction because it is relatively unique,” Prince said. “For individuals, there’s other platforms that have that.”

Daily Debrief Newsletter

Start every day with the top news stories right now, plus original features, a podcast, videos and more.



Source link

Ring-a-Ding Launches OpenClaw Skill for AI Agent Phone Calls | Web3Wire

0
Ring-a-Ding Launches OpenClaw Skill for AI Agent Phone Calls | Web3Wire


RALEIGH, N.C, April 18, 2026 (GLOBE NEWSWIRE) — Ring-a-Ding, a new OpenClaw skill for AI agent telephony, launched today to give AI agents the ability to make outbound phone calls for everyday tasks such as requesting quotes, booking appointments and checking availability. The tool installs through a command-line interface and

According to the company, many real-world tasks still require phone calls even as AI agents have become more capable in areas such as web research, email and file management. Ring-a-Ding was developed to help bridge that gap by handling phone number provisioning, SIP connectivity, real-time voice routing, call transcription and summaries behind the scenes.

The company said the skill is built for dynamic, one-to-one calls in which an AI agent generates the purpose and context of each conversation at the time of the call. Examples include contacting service providers for pricing, confirming reservations, checking store inventory or gathering structured information from a business by phone. Ring-a-Ding said the product is intended for legitimate task-based calls and prohibits sales calls, marketing outreach and robocalling.

Ring-a-Ding is available for $19 per month under a bring-your-own-key model, in which users provide their own OpenAI API key for voice AI while Ring-a-Ding manages the telephony layer. The company said each subscription includes outbound AI phone calls, a managed U.S. phone number pool, real-time voice bridging, transcripts, summaries and OpenClaw CLI integration. The skill is also designed to work as an MCP server for use with other compatible AI agents.

“Hundreds of things I need to get done every week still require a phone call,” said Vitaliy Levit, founder of Ring-a-Ding. “I wanted my OpenClaw agent to handle those calls for me without having to build a full voice infrastructure stack first.”

SMS messaging and inbound call handling are on the product roadmap, according to the company.

About Ring-a-DingRing-a-Ding is an OpenClaw skill for AI agent telephony that enables outbound phone calls by managing phone numbers, SIP connectivity, real-time voice routing and call transcription. The company said the product also functions as an MCP server for other compatible AI agents.

About Web3Wire Web3Wire – Information, news, press releases, events and research articles about Web3, Metaverse, Blockchain, Artificial Intelligence, Cryptocurrencies, Decentralized Finance, NFTs and Gaming. Visit Web3Wire for Web3 News and Events, Block3Wire for the latest Blockchain news and Meta3Wire to stay updated with Metaverse News.



Source link

OpenAI’s New AI Model Rosalind Could Shave Years Off Drug Discovery. You Probably Can’t Use It – Decrypt

0
OpenAI’s New AI Model Rosalind Could Shave Years Off Drug Discovery. You Probably Can’t Use It – Decrypt


In brief

OpenAI unveiled GPT-Rosalind to accelerate drug discovery workflows.
Benchmarks show strong gains, but real-world impact remains constrained .
Access is tightly restricted amid rising biosecurity concerns.

OpenAI just named its first domain-specific AI model after Rosalind Franklin—the British chemist whose X-ray crystallography work helped reveal DNA’s double helix, and who was famously denied credit for it during her lifetime.

GPT-Rosalind, unveiled Thursday, is a purpose-built reasoning model for biology, drug discovery, and translational medicine. It’s the first in what OpenAI is calling a Life Sciences model series—a direct play for a market where many specialized labs from universities to Google DeepMind are all jostling for position.

Getting a drug from target discovery to regulatory approval in the U.S. takes 10 to 15 years on average according to experts.. Most of that time disappears not in eureka moments, but in the grind: parsing thousands of papers, querying databases, designing reagents, and interpreting ambiguous results. This is what GPT-Rosaling is trying to tackle.

OpenAI argues the model can compress that early-stage work. As the company put it, GPT-Rosalind is designed to help scientists “explore more possibilities, surface connections that might otherwise be missed, and arrive at better hypotheses sooner.”



The benchmarks back up at least some of that ambition. On BixBench—a benchmark built around real-world bioinformatics tasks—GPT-Rosalind logged a 0.751 pass rate, the top score among models with published results. On LABBench2, it outperformed its predecessor GPT-5.4 on six out of eleven tasks.

GPT-Rosalind Beats GPT 5.4 in every single case involving life science, but it’s a highly specific model that will underperform in anything other than that.

OpenAI also announced Dyno Therapeutics will help test and evaluate its model based on unpublished RNA sequences to rule out memorization. GPT-Rosalind’s best-of-ten submissions ranked above the 95th percentile of human experts on sequence prediction tasks, and around the 84th percentile on generation.

That said, OpenAI’s own life sciences research lead Joy Jiao was measured about what the model can actually do. She explained the company doesn’t see Rosalind as a model capable of creating new treatments autonomously, but told reporters that it could be a great help in speeding research up. “We do think there’s a real opportunity to help researchers move faster through some of the most complex and time-intensive parts of the scientific process,” Jiao said in a press briefing, according to the LA Times.

The ecosystem around the model may matter as much as the model itself. OpenAI is also releasing a free Life Sciences research plugin for Codex connecting to over 50 scientific databases and tools—protein structure lookups, sequence search, literature review, genomics pipelines. Enterprise users with GPT-Rosalind access get the reasoning layer on top. Everyone else gets the plugin with standard models.

OpenAI has lined up a roster of pharma and biotech customers for the launch, including Amgen, Moderna, and Thermo Fisher Scientific. Separately, it’s running a research collaboration with Los Alamos National Laboratory on AI-guided protein and catalyst design.

“The life sciences field demands precision at every step. The questions are highly complex, the data are highly unique, and the stakes are incredibly high,” said Sean Bruich, Amgen’s Senior VP of AI and Data in the official announcement.

Access to Rosalind is deliberately restricted. The model is U.S. enterprise only, gated behind a qualification and safety review. The concern isn’t abstract: an international coalition of over 100 scientists has already called for tighter controls on biological data used to train AI, citing pathogen design risks. OpenAI’s restricted rollout is a direct response. During the research preview, usage won’t consume existing API credits.

This also isn’t OpenAI’s first move into science workflows. The Prism scientific writing workspace launched in January was a first step. GPT-Rosalind is the sharper, more specialized follow-up—and a signal that domain-specific models are becoming a serious competitive front.

No fully AI-discovered drug has cleared phase 3 trials. That number is still zero. But if GPT-Rosalind helps a researcher design a better experiment six months faster across thousands of labs, then the compounding effect on what gets discovered, and when, could be the whole ballgame. That’s the actual thesis here, and it’s worth watching closely.

Daily Debrief Newsletter

Start every day with the top news stories right now, plus original features, a podcast, videos and more.



Source link

RedCloud Holdings Plc Receives Notice Regarding Minimum Bid Price Requirement | Web3Wire

0
RedCloud Holdings Plc Receives Notice Regarding Minimum Bid Price Requirement | Web3Wire


London, UK, April 17, 2026 (GLOBE NEWSWIRE) — RedCloud Holdings plc (Nasdaq: RCT) (“RedCloud” or the “Company”), today disclosed that on April 15, 2026, it received formal notification from Nasdaq indicating that, based on the closing bid price of the Company’s ordinary shares for the last 30 consecutive business days, the Company is no longer in compliance with Nasdaq Listing Rule 5550(a)(2), which requires listed companies to maintain a minimum bid price of at least $1 per share.

Nasdaq Listing Rule 5810(c)(3)(A) provides a compliance period of 180 calendar days, or until October 12, 2026, in which to regain compliance with the minimum bid price requirement. If the Company evidences a closing bid price of at least $1 per share for a minimum of 10 consecutive business days during the 180-day compliance period, the Company will automatically regain compliance. In the event the Company does not regain compliance with the $1 bid price requirement by October 12, 2026, the Company may be eligible for consideration of a second 180-day compliance period if it meets the continued listing requirement for market value of publicly held shares and all other initial listing standards for Nasdaq’s Capital Market, other than the minimum bid price requirement. In addition, the Company would also be required to notify Nasdaq of its intent to cure the minimum bid price deficiency.

If the Company fails to regain compliance with the Nasdaq continued listing standards, Nasdaq will provide notice that the Company’s common stock will be subject to delisting.

The Company would then be entitled to appeal that determination to a Nasdaq hearings panel.

The notification has no immediate effect on the listing of the Company’s ordinary shares on Nasdaq. The Company is actively pursuing its commercial strategy, including the announcement of its joint venture operations, and is focused on regaining compliance within the 180-day period.

About RedCloud Holdings plc

RedCloud’s mission is to build the intelligence infrastructure of global trade, through generation and aggregation of proprietary trading and market data from across the FMCG industry through its RedAI platform (“RedAI”). RedCloud provides market intelligence based on proprietary trading data across categories in each of its markets. The Company also delivers a ‘trading layer’ of products for use by its customers, to enable intelligent digital exchange of everyday consumer supplies of FMCG products across business supply chains, supported by a payments and lending ecosystem intended to streamline trade. RedCloud believes its Platform and associated products and services solve a decades-old problem of how to digitize trade at scale to generate data and intelligence to enable brands, distributors and retailers to maximize business performance across categories in high growth consumer markets.

RedCloud is a British company registered in London, co-founded by Justin Floyd and Soumaya Hamzaoui. For more information about RedCloud and its Platform, please visit http://www.redcloudtechnology.com and connect on LinkedIn.

Forward-Looking Statements

The information in this press release may include forward-looking statements within the meaning of the federal securities laws. These statements generally relate to future events or our future financial or operating performance. When used in this press release, words such as “expect,” “project,” “estimate,” “believe,” “anticipate,” “intend,” “plan,” “seek,” “forecast,” “target,” “predict,” “may,” “should,” “would,” “could,” and “will,” the negative of these terms and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. Forward-looking statements are based on management’s current expectations and assumptions, and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict, including its ability to regain compliance with the minimum bid price listing requirement provided under Nasdaq Listing Rule 5550(a)(2). As a result, actual results could differ materially from those indicated in these forward-looking statements. When considering these forward-looking statements, you should keep in mind the risk factors and other cautionary statements in RedCloud’s described in “Cautionary Note Regarding Forward-Looking Statements,” “Item 3. Key Information – D. Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in RedCloud’s Annual Report on Form 20-F for the year ended December 31, 2024, which was filed with the Securities and Exchange Commission (the “SEC”) on May 16, 2025, as well as other documents filed by the Company with the SEC. RedCloud undertakes no obligation and does not intend to update these forward-looking statements to reflect events or circumstances occurring after this press release. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Information contained on, or that can be accessed through, the Company’s website or any other website or any social media is expressly not incorporated by reference into and is not a part of this press release.

Contacts:

Investor RelationsInvestor.relations@redcloudtechnology.com

Media Relationsmedia@redcloudtechnology.com

About Web3Wire Web3Wire – Information, news, press releases, events and research articles about Web3, Metaverse, Blockchain, Artificial Intelligence, Cryptocurrencies, Decentralized Finance, NFTs and Gaming. Visit Web3Wire for Web3 News and Events, Block3Wire for the latest Blockchain news and Meta3Wire to stay updated with Metaverse News.



Source link

Bitcoin Cracks 7-Month Ceiling. Can Bulls Push It Higher? – Decrypt

0
Bitcoin Cracks 7-Month Ceiling. Can Bulls Push It Higher? – Decrypt


In brief

Bitcoin jumped 2.7%, breaking the descending resistance line that had capped every rally since October.
Myriad traders have flipped bullish, giving BTC a 69% chance of hitting $84K next.
Traders, though, give a new Bitcoin all-time high only a 6.2% chance of happening before July.

Bitcoin is surging today on a geopolitical trigger few predicted: Iran today announced the Strait of Hormuz (or Strait of Iran, as President Donald Trump now calls it) will remain fully open during the ongoing ceasefire. It sent oil prices tumbling and risk assets surging in tandem.

Bitcoin climbed above $78,000 intraday on the news before pulling back slightly, while digital asset treasury stocks like Strategy surged more than 10% as BTC’s rise pushed its holdings back out of the red.

The macro environment had been brutal for most of 2026 with Middle East tensions, inflation fears, a strong dollar, and tight liquidity keeping Bitcoin locked in a grinding descent from its October 2025 peak of $126,000.

Bulls are praying that changes this week.

Bitcoin: Breaking the pattern, but not out of danger

Today’s candlestick on the Bitcoin charts is significant. Bitcoin opened at $75,172 and traders pushed the daily candle up to $77,205—a 2.7% gain on the session, with an intraday high of $78,384.

That move, modest as it sounds, was key to solidifying the thesis that the descending resistance trendline that had been rejecting Bitcoin at every rally attempt since October 2025 has been, finally, invalidated. For seven months, that line was gravity. This has been the first week Bitcoin trades over that line since the bearish pattern began.

Since the $126,000 all-time high, Bitcoin has traced a textbook descending channel—lower highs, lower lows, and a string of failed breakout attempts, each capped harder than the last. The yellow trendlines on the chart above show that, for months, Bitcoin registered a compression structure where each bounce got shallower, and each support got tested deeper.

If the trend had continued uninterrupted, the math was pointing toward $50,000–$55,000 as the logical next support zone. That scenario is now delayed, if not cancelled.

Indicators are also looking promising for bulls. The Exponential Moving Averages, which give traders a sense of the underlying trend based on smoothed price history, are still bearish with the 50-day EMA sitting below the 200-day EMA—a pattern that traders refer to as a death cross.

This matters because traders read the death cross as a bearish structural signal: The short-term trend is still weaker than the long-term average, meaning the recovery hasn’t been deep or sustained enough to flip the larger trend. The death cross doesn’t mean Bitcoin falls from here. It means bulls still have a mountain to climb before this is officially a new uptrend.

But it is the first time since January that the gap between both averages starts to compress.

The Average Directional Index, or ADX, reads 18.1, which means the current bearish trend is weak. ADX measures trend strength, not direction. A reading below 25 typically tells traders that the market lacks conviction and prices can move, but there’s no real engine behind them yet. Considering the markets have been bearish for almost half the year, a weak ADX means this trend may either be fading away or traders are accumulating as much as possible in this zone.

The Relative Strength Index, or RSI, is at 67.7, which means Bitcoin is overbought but still in a manageable zone. RSI measures the speed and magnitude of price changes on a scale of 0–100. Above 70 is traditionally considered overbought—territory where traders begin locking in profits. At 67.7, Bitcoin is close to that line but hasn’t crossed it yet, leaving some room for continuation before the technical pressure to sell intensifies.

The vertical lines in the background in the Bitcoin chart above show the squeeze momentum indicator (which tells when prices compress before a major spike in either direction) has been released, with positive momentum.

Predictions on Myriad

On Myriad, a prediction market developed by Decrypt’s parent company Dastan, traders are leaning bullish on Bitcoin’s next major move. Right now, Myriad traders are placing 69% odds on Bitcoin hitting $84K before dropping to $55K. The gap in favor of a Bitcoin pump is the widest it’s been since the market debuted back in early February.

But the same crowd is sober about timelines. A separate Myriad market gives Bitcoin only a 6% chance of hitting a new all-time high before July.



Overall, in an optimistic scenario, Bitcoin holds above the broken trendline (now acting as support around $74,000–$75,000), and the ADX begins climbing above 20–25. If bears take over again, a new rejection, combined with RSI rolling over from near-overbought levels, sends Bitcoin back to test the support area. A break below that turns the broken resistance back into resistance, invalidating the breakout.

Disclaimer

The views and opinions expressed by the author are for informational purposes only and do not constitute financial, investment, or other advice.

Daily Debrief Newsletter

Start every day with the top news stories right now, plus original features, a podcast, videos and more.



Source link

Rep. Sheri Biggs Doubles Down on Bitcoin, Buys Up to $250K of BlackRock’s ETF – Decrypt

0
Rep. Sheri Biggs Doubles Down on Bitcoin, Buys Up to 0K of BlackRock’s ETF – Decrypt



In brief

Rep. Sheri Biggs (R-SC) disclosed on Friday that she purchased up to $250,000 worth of BlackRock’s spot Bitcoin ETF (IBIT) last month.
The U.S. lawmaker “strongly supports crypto,” according to the Stand With Crypto Alliance, a grassroots advocacy group launched by Coinbase.
Biggs also bet on Bitcoin last July, disclosing another IBIT purchase that was valued at up to $250,000.

Rep. Sheri Biggs (R-SC) disclosed on Friday that she purchased up to $250,000 worth of BlackRock’s spot Bitcoin ETF (IBIT) last month, marking the conservative House member’s latest bet on the leading digital asset by market capitalization.

The purchase could have been as little as $100,000, Unusual Whales data showed, because U.S. lawmakers are only required to disclose the value of trades within a broad range.

Around the time that she scooped up Wall Street’s most popular vehicle for Bitcoin exposure, Biggs purchased shares in a private credit fund offered by asset manager Apollo. Meanwhile, the representative sold a similar product established by Apollo competitor Oaktree.

Biggs’ latest IBIT purchase was made on March 4, a few days after the U.S.-Israel war with Iran broke out. At the time, Bitcoin was valued as low as $67,800, according to CoinGecko. Bitcoin’s price has jumped around 14% since that nadir.



Over time, investments associated with digital assets have become commonplace among U.S. lawmakers, from meme coins to shares in Strategy (MSTR), the Bitcoin-buying behemoth. Former Rep. Marjorie Taylor Greene (R-GA) was the last politician to disclose a purchase of BlackRock’s spot Bitcoin ETF last November that was valued between $1,000 and $15,000.

Although Biggs’ official congressional homepage is devoid of language associated with digital assets, the representative is viewed as someone who “strongly supports crypto” by the Stand With Crypto Alliance, a grassroots advocacy group launched by Coinbase.

The advocacy group says Biggs has voted for three pro-crypto bills in the House: the CLARITY Act, the GENIUS Act, and H.J. Res 25, a resolution enacted last year that nullified tax reporting requirements for decentralized finance projects, viewed by some lawmakers as “burdensome.”

The congresswoman, who was sworn in as a representative of South Carolina’s 3rd Congressional District last January, appears to have previously violated the Stop Trading on Congressional Knowledge Act, or Stock Act, per an analysis by NOTUS.

The publication reported last October that Biggs apparently failed to meet a 45-day deadline while disclosing more than 170 trades made by her and her husband, which included another investment in BlackRock’s spot Bitcoin ETF of up to $250,000 last July. 

The representative’s latest IBIT purchase, made on March 4, indicated that Biggs had one day left under the law to make the trade’s details publicly available.

Decrypt has reached out to Biggs’ office for comment.

Daily Debrief Newsletter

Start every day with the top news stories right now, plus original features, a podcast, videos and more.



Source link

UBestmall LIMITED Launches Its Fully Upgraded 2026 Platform, Leading the Cryptocurrency Shopping Revolution | Web3Wire

0
UBestmall LIMITED Launches Its Fully Upgraded 2026 Platform, Leading the Cryptocurrency Shopping Revolution | Web3Wire


As cryptocurrency adoption continues to reshape global commerce, UBestmall has officially launched its fully upgraded 2026 platform, marking a major milestone in its mission to lead the cryptocurrency shopping revolution. As one of the earliest comprehensive e-commerce platforms to support crypto payments at scale, UBestmall is redefining how consumers and merchants connect across borders in the digital economy.

 

 

Designed to meet the growing demand for seamless, borderless shopping, the new UBestmall platform introduces enhanced system performance, improved user experience, and a more robust global collaboration framework. By leveraging cryptocurrency payments—represented by widely adopted stablecoins such as USDT—UBestmall continues to eliminate traditional payment friction and unlock truly global access to online retail.

 

 

“Our vision from the very beginning has been to remove barriers in global commerce,” said Hendrick William Offenberg, Founder of UBestmall. “The 2026 platform upgrade is not just a technical evolution—it represents our long-term commitment to building an open, inclusive, and efficient crypto shopping ecosystem for users worldwide.”

Industry Recognition and Academic Insight

UBestmall’s development has drawn attention from economists and fintech scholars in Canada. Professor Vincent Chen, Director of the FinTech Innovation Centre at the University of Toronto’s Rotman School of Management, commented:

“UBestmall sits at the intersection of two defining trends: the mainstreaming of cryptocurrency payments and the rise of distributed global collaboration. It is not simply an e-commerce platform, but a network-based ecosystem that integrates decentralized procurement and fulfillment through crypto-enabled infrastructure.”

 

 

An international trade expert from the University of British Columbia’s Sauder School of Business added that UBestmall’s strategic shift toward global crypto-commerce addresses a long-standing challenge in cross-border trade—payment efficiency and settlement complexity—offering a valuable reference model for technology-driven international expansion.

 

 

Building a Global Crypto-Commerce Ecosystem

Entering 2026, UBestmall is accelerating the expansion of its global footprint. The platform now offers a rapidly growing and diversified product matrix covering daily necessities, consumer electronics, toys, and lifestyle goods, serving users across multiple regions. Supported by its crypto-native architecture and first-mover advantage, UBestmall is steadily positioning itself as a next-generation global e-commerce platform.

Industry observers note that UBestmall’s differentiated positioning—combining cryptocurrency payments with a distributed operational model—places it on a distinct growth path alongside traditional e-commerce giants.

 

 

The “Collaborator Model”: Powering Sustainable Growth

At the core of UBestmall’s expansion is its pioneering Collaborator Model, which invites partners worldwide to participate directly in supply chain operations and platform development. This model has proven instrumental in:

Enabling flexible and efficient global supply chain expansion

Creating accessible participation opportunities for individuals and small teams worldwide

Establishing a resilient, decentralized operational network that supports long-term scalability

By aligning incentives across its ecosystem, UBestmall continues to strengthen its foundation as a collaborative, globally connected commerce platform.

Commitment to Partners and the Future

UBestmall emphasizes that partnership remains central to its strategy. “Our collaborators are not external contributors—they are part of the platform’s core,” Offenberg added. “As we move forward, we will continue investing in technology, compliance, and ecosystem growth to ensure that everyone who participates can grow with us.”

With the launch of its 2026 upgraded platform, UBestmall signals a new chapter in crypto-enabled e-commerce—one focused on innovation, collaboration, and redefining the future of global shopping.

Contact:

UBestmall Media Relations Department

Contact: Hedrik Offenberg

Email: [email protected]

Website: http://www.ubestmall.com

Disclaimer: The information provided in this press release is not a solicitation for investment, nor is it intended as investment advice, financial advice, or trading advice. Investing involves risk, including the potential loss of capital. It is strongly recommended you practice due diligence, including consultation with a professional financial advisor, before investing in or trading cryptocurrency and securities. Neither the media platform nor the publisher shall be held responsible for any fraudulent activities, misrepresentations, or financial losses arising from the content of this press release.

About Web3Wire Web3Wire – Information, news, press releases, events and research articles about Web3, Metaverse, Blockchain, Artificial Intelligence, Cryptocurrencies, Decentralized Finance, NFTs and Gaming. Visit Web3Wire for Web3 News and Events, Block3Wire for the latest Blockchain news and Meta3Wire to stay updated with Metaverse News.



Source link

Popular Posts

My Favorites

Mira (MIRA) Will Be Listed on Binance HODLer Airdrops

0
Mira is the 45th project to be featured on Binance HODLer Airdrops. The MIRA token will be available on the Binance Spot Market...